Ascendiant Capital Maintains Buy on Biolase, Lowers Price Target to $4
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital analyst Edward Woo maintains a Buy rating on Biolase (NASDAQ:BIOL) but lowers the price target from $15 to $4.

April 01, 2024 | 9:40 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ascendiant Capital maintains a Buy rating on Biolase but significantly reduces the price target from $15 to $4.
The reduction in price target from $15 to $4 by Ascendiant Capital, despite maintaining a Buy rating, could lead to negative investor sentiment in the short term. This significant decrease in the price target may cause concerns about the company's future growth prospects or financial health, potentially leading to a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100